{"id":47711,"date":"2022-08-26T17:01:56","date_gmt":"2022-08-26T15:01:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/"},"modified":"2022-08-26T17:01:56","modified_gmt":"2022-08-26T15:01:56","slug":"global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/","title":{"rendered":"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5644885\/global-her2-negative-breast-cancer-pipeline?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=psqnx2&amp;utm_campaign=1742740+-+Global+HER2-Negative+Breast+Cancer+Drug+Pipeline+Research+Report+2022%3A+Comprehensive+Insights+About+85%2B+Companies+and+85%2B+Pipeline+Drugs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Global HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221;<\/a> drug pipelines has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis &#8220;HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n<p>\nThe report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2-Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HER2-Negative Breast Cancer treatment guidelines.\n<\/p>\n<p>\nThe assessment part of the report embraces, in depth HER2-Negative Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n<p>\nThe companies and academics are working to assess challenges and seek opportunities that could influence HER2-Negative Breast Cancer R&amp;D. The therapies under development are focused on novel approaches to treat\/improve HER2-Negative Breast Cancer.\n<\/p>\n<p>\n<strong>HER2-Negative Breast Cancer Emerging Drugs Chapters<\/strong>\n<\/p>\n<p>\nThis segment of the HER2-Negative Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n<p>\n<strong>HER2-Negative Breast Cancer Emerging Drugs<\/strong>\n<\/p>\n<p>\n<strong>Capivasertib + Fulvestrant: AstraZeneca<\/strong>\n<\/p>\n<p>\nCapivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine\/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+\/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.\n<\/p>\n<p>\n<strong>Dalpiciclib: Jiangsu HengRui<\/strong>\n<\/p>\n<p>\nMedicineDalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4\/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent\/Metastatic Breast Cancer.\n<\/p>\n<p>\n<strong>HER2-Negative Breast Cancer: Therapeutic Assessment<\/strong>\n<\/p>\n<p>\nThis segment of the report provides insights about the different HER2-Negative Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n<p>\n<strong>Major Players in HER2-Negative Breast Cancer<\/strong>\n<\/p>\n<p>\nThere are approx. 85+ key companies which are developing the therapies for HER2-Negative Breast Cancer. The companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.\n<\/p>\n<p>\n<strong>Phases<\/strong>\n<\/p>\n<p>\n<strong>This report covers around 85+ products under different phases of clinical development like<\/strong>\n<\/p>\n<ul>\n<li>\nLate stage products (Phase III)\n<\/li>\n<li>\nMid-stage products (Phase II)\n<\/li>\n<li>\nEarly-stage product (Phase I)\n<\/li>\n<li>\nPre-clinical and Discovery stage candidates\n<\/li>\n<li>\nDiscontinued &amp; Inactive candidates\n<\/li>\n<li>\nRoute of Administration\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n<ul>\n<li>\nOral\n<\/li>\n<li>\nParenteral\n<\/li>\n<li>\nIntravitreal\n<\/li>\n<li>\nSubretinal\n<\/li>\n<li>\nTopical\n<\/li>\n<li>\nMolecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>Products have been categorized under various Molecule types such as<\/strong>\n<\/p>\n<ul>\n<li>\nMonoclonal Antibody\n<\/li>\n<li>\nPeptides\n<\/li>\n<li>\nPolymer\n<\/li>\n<li>\nSmall molecule\n<\/li>\n<li>\nGene therapy\n<\/li>\n<li>\nProduct Type\n<\/li>\n<\/ul>\n<p>\nDrugs have been categorized under various product types like Mono, Combination and Mono\/Combination.\n<\/p>\n<p>\n<strong>HER2-Negative Breast Cancer: Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HER2-Negative Breast Cancer therapeutic drugs key players involved in developing key drugs.\n<\/p>\n<p>\n<strong>Pipeline Development Activities<\/strong>\n<\/p>\n<p>\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2-Negative Breast Cancer drugs.\n<\/p>\n<p>\n<strong>HER2-Negative Breast Cancer Report Insights<\/strong>\n<\/p>\n<ul>\n<li>\nHER2-Negative Breast Cancer Pipeline Analysis\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<li>\nImpact of Drugs\n<\/li>\n<\/ul>\n<p>\n<strong>HER2-Negative Breast Cancer Report Assessment<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Product Profiles\n<\/li>\n<li>\nTherapeutic Assessment\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nInactive drugs assessment\n<\/li>\n<li>\nUnmet Needs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Players<\/strong>\n<\/p>\n<ul>\n<li>\nAstraZeneca\n<\/li>\n<li>\nLaekna\n<\/li>\n<li>\nNovartis\n<\/li>\n<li>\nJiangsu HengRui Medicine\n<\/li>\n<li>\nRoche\n<\/li>\n<li>\nOlema Pharmaceuticals\n<\/li>\n<li>\nHaihe Biopharma\n<\/li>\n<li>\nG1 Therapeutics\n<\/li>\n<li>\nMerck\n<\/li>\n<li>\nChia Tai Tianqing Pharmaceutical\n<\/li>\n<li>\nTyme\n<\/li>\n<li>\nRadius Pharmaceuticals\n<\/li>\n<li>\nH3 Biomedicine\n<\/li>\n<li>\nEli Lilly and Company\n<\/li>\n<li>\nEagle Pharmaceuticals\n<\/li>\n<\/ul>\n<p>\n<strong>Key Products<\/strong>\n<\/p>\n<ul>\n<li>\nCapivasertib\n<\/li>\n<li>\nAfuresertib\n<\/li>\n<li>\nDalpiciclib\n<\/li>\n<li>\nInavolisib\n<\/li>\n<li>\nOP-1250\n<\/li>\n<li>\nCYH33\n<\/li>\n<li>\nLerociclib\n<\/li>\n<li>\nPembrolizumab\n<\/li>\n<li>\nTQB3616\n<\/li>\n<li>\nSM-88\n<\/li>\n<li>\nElacestrant\n<\/li>\n<li>\nH3B-6545\n<\/li>\n<li>\nFulvestrant\n<\/li>\n<\/ul>\n<p>\nFor more information about this drug pipelines report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5644885\/global-her2-negative-breast-cancer-pipeline?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=psqnx2&amp;utm_campaign=1742740+-+Global+HER2-Negative+Breast+Cancer+Drug+Pipeline+Research+Report+2022%3A+Comprehensive+Insights+About+85%2B+Companies+and+85%2B+Pipeline+Drugs&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/rdjd4a<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x70;&#x72;es&#115;&#64;&#114;&#x65;&#x73;&#x65;&#x61;rc&#104;&#97;&#110;&#x64;&#x6d;&#x61;&#x72;ke&#116;&#115;&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;r&#x65;&#115;&#x73;&#x40;r&#x65;&#115;&#x65;&#x61;r&#x63;&#104;&#x61;&#x6e;d&#x6d;&#97;&#x72;&#x6b;e&#x74;&#115;&#x2e;&#x63;o&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47711","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-26T15:01:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-08-26T15:01:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/\"},\"wordCount\":806,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220826005339\\\/en\\\/1554571\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/\",\"name\":\"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220826005339\\\/en\\\/1554571\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-08-26T15:01:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220826005339\\\/en\\\/1554571\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220826005339\\\/en\\\/1554571\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; drug pipelines has been added to ResearchAndMarkets.com&#8217;s offering. This &#8220;HER2-Negative Breast Cancer &#8211; Pipeline Insight, 2022&#8221; report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-26T15:01:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs &#8211; ResearchAndMarkets.com","datePublished":"2022-08-26T15:01:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/"},"wordCount":806,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/","name":"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg","datePublished":"2022-08-26T15:01:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220826005339\/en\/1554571\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-her2-negative-breast-cancer-drug-pipeline-research-report-2022-comprehensive-insights-about-85-companies-and-85-pipeline-drugs-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global HER2-Negative Breast Cancer Drug Pipeline Research Report 2022: Comprehensive Insights About 85+ Companies and 85+ Pipeline Drugs &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47711"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47711\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}